Occam Recruits Michelle Robertson as CFO of Geron Corporation

Geron Corporation (Nasdaq: GERN), is a late-stage clinical biopharmaceutical company focused on the development and commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.  In September 2023, Occam placed Michelle Robertson as EVP, Chief Financial Officer and Treasurer.

Michelle joins Geron at an exciting time in the company's evolution, on the verge of potential commercialization of its first product.  She brings to Geron 30 years of financial and commercial operations experience. Most recently, Michelle served as CFO and Treasurer of Editas Medicine, where she raised $0.5B in capital to support that company's transition to late-stage clinical development. Before that, she was CFO of Momenta Pharmaceuticals, leading a financial restructuring in preparation for that company's acquisition by J&J.  

Geron is a longstanding client for whom Occam recently placed Chief Legal Officer and Corporate Secretary Scott Samuels.  Occam previously recruited three independent Board members, John McDonald, Dawn Bir, and Liz O'Farrell; Chief Business Officer Edward Koval; and VP Investor Relations & Corporate Communications Aron Feingold.

‍